Federal Register #2026-21368

DEA notice regarding Groff Health Inc.’s application to bulk-manufacture four controlled substances

The Drug Enforcement Administration notice concerns Groff Health Inc.’s application to manufacture four controlled substances in bulk. - Government buyer: U.S. Department of Justice, Drug Enforcement Administration (DEA); no specific sub-agency office is identified. - Applicant/manufacturer: Groff Health Inc. proposes to manufacture the substances for internal use and sale to its customers. - Substances listed: - Ibogaine — drug code 7260 - 3,4-Methylenedioxymethamphetamine — drug code 7405 - Psilocybin — drug code 7437 - Psilocyn — drug code 7438 - The notice states that no other activities for these drug codes are authorized under the proposed registration. - This is a regulatory application notice, not a procurement solicitation or award; no purchase quantities, contract value, or performance period are specified.

Description

Groff Health Inc has applied to be registered as a bulk manufacturer of the listed basic classes of controlled substances. The company plans to manufacture the substances for internal use and sale to its customers. No other activities for the listed drug codes are authorized under the proposed registration. Registered bulk manufacturers and applicants may submit comments or objections, or request a hearing, by December 18, 2026.

View original listing